department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

SANDIMMUNE · pharmadog

pharmadog
drugs
SANDIMMUNE

drug · protein

patient view →

SANDIMMUNE

updated 2mo ago

/ /ˌsaɪkləˈspɔrɪn/ /

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

Protein drug with a maximum clinical stage of Approval (across all indications), with 12 approved and 71 investigational indications.

targets

Peptidyl-prolyl cis-trans isomerase A

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

SANDIMMUNE

trade names

Capimune, Capsorin, Cequa, Cyclosporine, Deximune, Gengraf

generic

CYCLOSPORINE

MOA

Cyclophilin A modulator

indication

INDICATIONS AND USAGE Sandimmune capsules and Sandimmune injection, in combination with adrenal corticosteroids, are indicated for the: Prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Treatment of chronic rejection in patients previously treated with other immunosuppressive agents. Because of the risk of anaphylaxis, Sandimmune injection should be reserved for patients who are unable to take the Sandimmune capsules.

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 6

tagApproval492 co-mentions · 124 sources
drugCYCLOSPORINE491 co-mentions · 125 sources
drugRestasis247 co-mentions · 125 sources
drugCequa247 co-mentions · 125 sources
tagSmall Molecule172 co-mentions · 86 sources
tagRecall1 co-mentions · 1 sources

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying SANDIMMUNE

phase4Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunctionrecruitingn=48
phase4Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeksnot yet recruitingn=60
—Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Studyrecruitingn=50
phase3Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)terminatedn=164
phase2Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemiarecruitingn=20
phase2Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignanciesrecruitingn=60
phase3Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)completedn=169
phase3A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medicationsrecruitingn=102

more trials →